Celgene (NASDAQ:CELG) received a $166.00 target price from Oppenheimer in a research report issued on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective points to a potential upside of 53.42% from the stock’s previous close.

Several other research firms also recently weighed in on CELG. BMO Capital Markets raised their price target on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, November 17th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research report on Monday, October 23rd. Cann restated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. Finally, Citigroup cut their price objective on shares of Celgene from $140.00 to $102.00 and set a “neutral” rating for the company in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. Celgene has an average rating of “Buy” and an average price target of $136.21.

Celgene (NASDAQ:CELG) opened at $108.20 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market cap of $85,849.04, a PE ratio of 17.04, a PEG ratio of 0.84 and a beta of 1.78. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $1.58 earnings per share. research analysts anticipate that Celgene will post 6.67 EPS for the current year.

In other Celgene news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.95% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Neuberger Berman Group LLC grew its holdings in shares of Celgene by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC acquired a new position in shares of Celgene in the second quarter valued at approximately $3,616,000. Lincoln Capital Corp grew its holdings in shares of Celgene by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares in the last quarter. RiverPoint Capital Management LLC grew its holdings in shares of Celgene by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after purchasing an additional 3,680 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Celgene by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after purchasing an additional 54,210 shares in the last quarter. Institutional investors and hedge funds own 80.16% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer Analysts Give Celgene (CELG) a $166.00 Price Target” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/oppenheimer-analysts-give-celgene-celg-a-166-00-price-target/1763032.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with Analyst Ratings Network's FREE daily email newsletter.